SlideShare una empresa de Scribd logo
1 de 31
REVISED FIGO STAGING
      SYSTEMS FOR
GYNAECOLOGICAL CANCERS
         (2009)
  Glenn McCluggage, Belfast Trust
BACKGROUND
• Groups set up several years ago
• March 2009-staging system for uterine
  sarcomas published (IJGO
  2009;104;179)- PATHOLOGICAL INPUT
• May 2009-staging systems for
  endometrial, cervical and vulval tumours
  published (IJGO 2009;105;103-104)- NO
  PATHOLOGICAL INPUT
OTHER TUMOURS
• groups set up to look at staging of ovarian,
  fallopian tube and trophoblastic
  neoplasms
NEW FIGO STAGING FOR
     UTERINE SARCOMAS
• never had staging system previously
• carcinosarcomas staged as per uterine
  carcinomas
• staging system for leiomyosarcomas
• different system for ESS and
  adenosarcoma
Leiomyosarcomas- FIGO 2009

Stage I     Tumour limited to uterus
IA          <5 cm
IB          >5 cm

Stage II    Tumour extends to the pelvis
IIA         Adnexal involvement
IIB         Tumour extends to extrauterine pelvic tissue

Stage III   Tumour invades abdominal tissues (not just protruding into the abdomen)
IIIA        One site
IIIB        > one site
IIIC        Metastasis to pelvic and/or para-aortic lymph nodes

Stage IV
IVA         Tumour invades bladder and/or rectum
IVB         Distant metastasis
Endometrial stromal sarcomas (ESS) and adenosarcomas- FIGO 2009


Stage I     Tumour limited to uterus
IA          Tumour limited to endometrium/endocervix with no myometrial invasion
IB          Less than or equal to half myometrial invasion
IC          More than half myometrial invasion

Stage II    Tumour extends to the pelvis
IIA         Adnexal involvement
IIB         Tumour extends to extrauterine pelvic tissue

Stage III   Tumour invades abdominal tissues (not just protruding into the abdomen)
IIIA        One site
IIIB        > one site
IIIC        Metastasis to pelvic and/or para-aortic lymph nodes

Stage IV
IVA         Tumour invades bladder and/or rectum
IVB         Distant metastasis
ENDOMETRIAL CARCINOMA
Carcinoma of the endometrium- FIGO 2009

Stage I     Tumour confined to the corpus uteri
IA          No or less than half myometrial invasion
IB          Invasion equal to or more than half of the myometrium

Stage II    Tumour invades cervical stroma, but does not extend beyond the uterus

Stage III   Local and/or regional spread of the tumour
IIIA        Tumour invades the serosa of the corpus uteri and/or adnexae
IIIB        Vaginal and/or parametrial involvement
IIIC        Metastases to pelvic and/or para-aortic lymph nodes
IIIC1       Positive pelvic nodes
IIIC2       Positive para-aortic lymph nodes with or without positive pelvic lymph nodes

Stage IV    Tumour invades bladder and/or bowel mucosa, and/or distant metastases
IVA         Tumour invasion of bladder and/or bowel mucosa
IVB         Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes
CHANGES TO STAGE I
• old IA and IB is now IA (FIGO figures
  show no difference in outcome;
  pathological difficulties)
• old IC is now IB
• endocervical glandular involvement alone
  will still be stage I
CHANGES TO STAGE II
• single category of stage II (cervical
  stromal involvement)
CHANGES TO STAGE III
• IIIA- uterine serosal or adnexal
  involvement
• IIIB- vaginal and/or parametrial
  involvement
• IIIC- pelvic and/or para-aortic nodes
  (IIIC1-pelvic nodes; IIIC2- para-aortic
  nodes)
CHANGES TO STAGE IV
• none
PERITONEAL WASHINGS
• to be performed and reported separately
  ie not part of staging system
• significance to be discussed at MDTM
PATHOLOGY PROFORMAS
• ? still include confined to endometrium or
  inner half of endometrium
• ? still include cervical glandular
  involvement (? will be treated with
  radiotherapy)
CERVICAL CARCINOMA
Carcinoma of the cervix uteri- FIGO 2009


Stage I    The carcinoma is strictly confined to the cervix (extension to the corpus would
           be disregarded)
IA         Invasive carcinoma which can be diagnosed only by microscopy, with deepest
           invasion <5 mm and the largest extension >7 mm
IA1        Measured stromal invasion of <3.0 mm in depth and extension of <7.0 mm
IA2        Measured stromal invasion of >3.0 mm and not >5.0 mm with an extension of
           not >7.0 mm
IB         Clinically visible lesions limited to the cervix uteri or pre-clinical cancers
           greater than stage IA
IB1        Clinically visible lesion <4.0 cm in greatest dimension
IB2        Clinically visible lesion >4.0 cm in greatest dimension

Stage II   Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower
           third of the vagina
IIA        Without parametrial invasion
IIA1       Clinically visible lesion <4.0 cm in greatest dimension
IIA2       Clinically visible lesion >4.0 cm in greatest dimension
IIB        With obvious parametrial invasion
Stage III   The tumour extends to the pelvic wall and/or involves lower third of the vagina and/or
            causes hydronephrosis or non-functioning kidney
IIIA        Tumour involves lower third of the vagina, with no extension to the pelvic wall
IIIB        Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney

Stage IV    The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the
            mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to
            be allotted to Stage IV
IVA         Spread of the growth to adjacent organs
IVB         Spread to distant organs
CERVICAL CARCINOMA
• no stage 0
CHANGES TO STAGE I
• none
CHANGES TO STAGE II
• IIA- without parametrial invasion ie vaginal
  involvement (IIA1- < 4cm; IIA2- >4cm)
CHANGES TO STAGE III
• none
CHANGES TO STAGE IV
• none
VULVAL CARCINOMA
• MUCH MORE COMPLICATED
• significant changes
Carcinoma of the vulva- FIGO 2009
Stage I     Tumour confined to the vulva
IA          Lesions <2 cm in size, confined to the vulva or perineum and with stromal
            invasions <1.0 mm*, no nodal metastasis
IB          Lesions >2 cm in size or with stromal invasion >1.0 mm* confined to the
            vulva or perineum, with negative nodes
Stage II    Tumour of any size with extension to adjacent perineal structures (1/3 lower
            urethra, 1/3 lower vagina, anus) with negative nodes
Stage III   Tumour of any size with or without extension to adjacent perineal structures
            (1/3 lower urethra, 1/3 lower vagina, anus) with positive inguino-femoral lymph nodes.
IIIA        (i) With 1 lymph node metastasis (>5 mm), or
            (ii) 1-2 lymph node metastasis(es) (<5 mm)
IIIB        (i) With 2 or more lymph node metastases (>5 mm), or
            (ii) 3 or more lymph node metastases (<5 mm)
IIIC        With positive nodes with extracapsular spread
Stage IV    Tumour invades other regional (2/3 upper urethra, 2/3 upper vagina), or distant structures.
IVA         Tumour invades any of the following:
            (i) upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, or
            fixed to pelvic bone, or
            (ii) fixed or ulcerated inguino-femoral lymph nodes
IVB         Any distant metastasis including pelvic lymph nodes

* The depth of invasion is defined as the measurement of the tumour from the epithelial-stromal
junction of the adjacent most superficial dermal papilla to the deepest point of invasion.
CHANGES TO STAGE I
• IA- < 2cm, stromal invasion <1mm,
  confined to vulval or perineum, no nodal
  metastasis
• IB- previous IB and II combined- >2cm
  size or with stromal invasion >1mm,
  confined to vulval or perineum, no nodal
  metastasis
CHANGES TO STAGE II
• any size with extension to lower third of
  urethra, lower third of vagina or anus and
  negative nodes
CHANGES TO STAGE III
• any size, with or without extension to
  lower third of urethra, lower third of vagina
  or anus and positive inguino-femoral
  nodes
• IIIA- 1 nodal metastasis > 5mm or up to 2
  nodes <5mm
• IIIB- 2 or more nodes >5mm or 3 or more
  nodes <5mm
• IIIC- extracapsular spread
CHANGES TO STAGE IV
• upper two thirds of urethra or vagina or
  distant structures
• various substages
• bilateral nodal involvement now not taken
  into account
IMPLICATIONS/DIFFICULTIES
• dissemination of information to surgical oncologists,
  gynaecologists, non-surgical oncologists, pathologists,
  radiologists
• ? set start date
• endocervical glandular involvement in endometrial
  cancer (marked interobserver variation)
• pathologists difficulty in distinguishing cervical glandular
  from stromal involvement
• TNM will differ for a while- will be updated in 7th TNM
  edition (? drop TNM from pathology proformas)
WIDER QUESTIONS
• rest of UK (role of British Gynaecological
  Cancer Society, British Association of
  Gynaecological Pathologists)
• if piecemeal introduction, will create
  difficulties

Más contenido relacionado

La actualidad más candente

Fibroid Removal In Day Care
Fibroid Removal In Day CareFibroid Removal In Day Care
Fibroid Removal In Day CareApollo Hospitals
 
Urology gynecology mri staging for ca cervix
Urology gynecology mri staging for ca cervixUrology gynecology mri staging for ca cervix
Urology gynecology mri staging for ca cervixJFIM
 
Cervical and broad ligament fibroid
Cervical and broad ligament fibroidCervical and broad ligament fibroid
Cervical and broad ligament fibroidNiranjan Chavan
 
46 magnetic resonance imaging of the female pelvis
46 magnetic resonance imaging of the female pelvis46 magnetic resonance imaging of the female pelvis
46 magnetic resonance imaging of the female pelvisDr. Muhammad Bin Zulfiqar
 
Endometriosis by Ultrasound
Endometriosis by UltrasoundEndometriosis by Ultrasound
Endometriosis by UltrasoundAqib Umair
 

La actualidad más candente (8)

Radical hysterectomy
Radical hysterectomyRadical hysterectomy
Radical hysterectomy
 
5.1
5.15.1
5.1
 
Fibroid Removal In Day Care
Fibroid Removal In Day CareFibroid Removal In Day Care
Fibroid Removal In Day Care
 
Benign lesions of cervix
Benign lesions of cervixBenign lesions of cervix
Benign lesions of cervix
 
Urology gynecology mri staging for ca cervix
Urology gynecology mri staging for ca cervixUrology gynecology mri staging for ca cervix
Urology gynecology mri staging for ca cervix
 
Cervical and broad ligament fibroid
Cervical and broad ligament fibroidCervical and broad ligament fibroid
Cervical and broad ligament fibroid
 
46 magnetic resonance imaging of the female pelvis
46 magnetic resonance imaging of the female pelvis46 magnetic resonance imaging of the female pelvis
46 magnetic resonance imaging of the female pelvis
 
Endometriosis by Ultrasound
Endometriosis by UltrasoundEndometriosis by Ultrasound
Endometriosis by Ultrasound
 

Destacado

cervical carcinoma, endometrial carcinoma and vulval disease
cervical carcinoma, endometrial carcinoma and vulval diseasecervical carcinoma, endometrial carcinoma and vulval disease
cervical carcinoma, endometrial carcinoma and vulval diseasessn zhd
 

Destacado (6)

Cervical Carcinoma
Cervical CarcinomaCervical Carcinoma
Cervical Carcinoma
 
cervical carcinoma, endometrial carcinoma and vulval disease
cervical carcinoma, endometrial carcinoma and vulval diseasecervical carcinoma, endometrial carcinoma and vulval disease
cervical carcinoma, endometrial carcinoma and vulval disease
 
Carcinoma cervix
Carcinoma cervixCarcinoma cervix
Carcinoma cervix
 
Endometrial carcinoma
Endometrial carcinomaEndometrial carcinoma
Endometrial carcinoma
 
Cervical carcinoma
Cervical carcinomaCervical carcinoma
Cervical carcinoma
 
Cervical carcinoma
Cervical carcinomaCervical carcinoma
Cervical carcinoma
 

Similar a Figo staging systems

Figo staging of genital cancers(FIGO)
Figo staging of genital cancers(FIGO)Figo staging of genital cancers(FIGO)
Figo staging of genital cancers(FIGO)namkha dorji
 
FIGO staging: ovarian, fallopian and peritoneal cancers. 2014
FIGO staging: ovarian, fallopian and peritoneal cancers. 2014FIGO staging: ovarian, fallopian and peritoneal cancers. 2014
FIGO staging: ovarian, fallopian and peritoneal cancers. 2014Dr Anusha Rao P
 
Simplified Gyn-Onc Staging system
Simplified Gyn-Onc Staging systemSimplified Gyn-Onc Staging system
Simplified Gyn-Onc Staging systemMauricio Lema
 
Surgical Management of Cervical Cancer 11052023 FOGSI PAC LECTURE WEBINAR.pptx
Surgical Management of Cervical Cancer 11052023 FOGSI PAC LECTURE WEBINAR.pptxSurgical Management of Cervical Cancer 11052023 FOGSI PAC LECTURE WEBINAR.pptx
Surgical Management of Cervical Cancer 11052023 FOGSI PAC LECTURE WEBINAR.pptxNiranjan Chavan
 
cervical cancer
 cervical cancer cervical cancer
cervical cancermt53y8
 
Endometril carcinoma
Endometril carcinoma Endometril carcinoma
Endometril carcinoma Alaa Badawi
 
Staging of cervical cancer - Copy.pptx
Staging of cervical cancer - Copy.pptxStaging of cervical cancer - Copy.pptx
Staging of cervical cancer - Copy.pptxpreetikumari1721
 
CES202101 - Clase 15 parte 1 - Cáncer de cérvix
CES202101 - Clase 15 parte 1 - Cáncer de cérvix CES202101 - Clase 15 parte 1 - Cáncer de cérvix
CES202101 - Clase 15 parte 1 - Cáncer de cérvix Mauricio Lema
 
cervical cancer.ppt by Dr. Rabirra Waktola
cervical cancer.ppt by Dr. Rabirra Waktolacervical cancer.ppt by Dr. Rabirra Waktola
cervical cancer.ppt by Dr. Rabirra WaktolaDrRabirraWaktola
 
FIGO Endometrium Staging 2023.pptx
FIGO Endometrium Staging 2023.pptxFIGO Endometrium Staging 2023.pptx
FIGO Endometrium Staging 2023.pptxKiron G
 
SURGICAL MANAGEMENT OF CERVICAL CANCER DR. NN CHAVAN 28102023.pptx
SURGICAL MANAGEMENT OF CERVICAL CANCER DR. NN CHAVAN 28102023.pptxSURGICAL MANAGEMENT OF CERVICAL CANCER DR. NN CHAVAN 28102023.pptx
SURGICAL MANAGEMENT OF CERVICAL CANCER DR. NN CHAVAN 28102023.pptxNiranjan Chavan
 
Condition affecting
Condition affectingCondition affecting
Condition affectingMagda Helmi
 
18.Cervical Cancer
18.Cervical Cancer18.Cervical Cancer
18.Cervical CancerDeep Deep
 
Gynaecological cancers staging and treatment
Gynaecological cancers   staging and treatmentGynaecological cancers   staging and treatment
Gynaecological cancers staging and treatmentsailakshmidaayana
 
Clasificación histopatológica del cáncer de ovario
Clasificación histopatológica del cáncer de ovarioClasificación histopatológica del cáncer de ovario
Clasificación histopatológica del cáncer de ovarioGabinete Médico Velázquez
 

Similar a Figo staging systems (20)

Figo staging of genital cancers(FIGO)
Figo staging of genital cancers(FIGO)Figo staging of genital cancers(FIGO)
Figo staging of genital cancers(FIGO)
 
FIGO staging: ovarian, fallopian and peritoneal cancers. 2014
FIGO staging: ovarian, fallopian and peritoneal cancers. 2014FIGO staging: ovarian, fallopian and peritoneal cancers. 2014
FIGO staging: ovarian, fallopian and peritoneal cancers. 2014
 
Figo 2018 ca cervix dodul mondal
Figo 2018 ca cervix dodul mondalFigo 2018 ca cervix dodul mondal
Figo 2018 ca cervix dodul mondal
 
Simplified Gyn-Onc Staging system
Simplified Gyn-Onc Staging systemSimplified Gyn-Onc Staging system
Simplified Gyn-Onc Staging system
 
Cancer cervix 2020
Cancer cervix 2020Cancer cervix 2020
Cancer cervix 2020
 
Surgical Management of Cervical Cancer 11052023 FOGSI PAC LECTURE WEBINAR.pptx
Surgical Management of Cervical Cancer 11052023 FOGSI PAC LECTURE WEBINAR.pptxSurgical Management of Cervical Cancer 11052023 FOGSI PAC LECTURE WEBINAR.pptx
Surgical Management of Cervical Cancer 11052023 FOGSI PAC LECTURE WEBINAR.pptx
 
CARCINOMA CERVIX
CARCINOMA CERVIXCARCINOMA CERVIX
CARCINOMA CERVIX
 
cervical cancer
 cervical cancer cervical cancer
cervical cancer
 
Endometril carcinoma
Endometril carcinoma Endometril carcinoma
Endometril carcinoma
 
Staging of cervical cancer - Copy.pptx
Staging of cervical cancer - Copy.pptxStaging of cervical cancer - Copy.pptx
Staging of cervical cancer - Copy.pptx
 
female tumor
female tumorfemale tumor
female tumor
 
CES202101 - Clase 15 parte 1 - Cáncer de cérvix
CES202101 - Clase 15 parte 1 - Cáncer de cérvix CES202101 - Clase 15 parte 1 - Cáncer de cérvix
CES202101 - Clase 15 parte 1 - Cáncer de cérvix
 
cervical cancer.ppt by Dr. Rabirra Waktola
cervical cancer.ppt by Dr. Rabirra Waktolacervical cancer.ppt by Dr. Rabirra Waktola
cervical cancer.ppt by Dr. Rabirra Waktola
 
FIGO Endometrium Staging 2023.pptx
FIGO Endometrium Staging 2023.pptxFIGO Endometrium Staging 2023.pptx
FIGO Endometrium Staging 2023.pptx
 
SURGICAL MANAGEMENT OF CERVICAL CANCER DR. NN CHAVAN 28102023.pptx
SURGICAL MANAGEMENT OF CERVICAL CANCER DR. NN CHAVAN 28102023.pptxSURGICAL MANAGEMENT OF CERVICAL CANCER DR. NN CHAVAN 28102023.pptx
SURGICAL MANAGEMENT OF CERVICAL CANCER DR. NN CHAVAN 28102023.pptx
 
Condition affecting
Condition affectingCondition affecting
Condition affecting
 
18.Cervical Cancer
18.Cervical Cancer18.Cervical Cancer
18.Cervical Cancer
 
Gynaecological cancers staging and treatment
Gynaecological cancers   staging and treatmentGynaecological cancers   staging and treatment
Gynaecological cancers staging and treatment
 
Clasificación histopatológica del cáncer de ovario
Clasificación histopatológica del cáncer de ovarioClasificación histopatológica del cáncer de ovario
Clasificación histopatológica del cáncer de ovario
 
Female Genital Tract Malignancies
Female Genital Tract Malignancies  Female Genital Tract Malignancies
Female Genital Tract Malignancies
 

Más de Subha Deep

ECG Basics with Prof Dr LK Meher.pptx
ECG Basics with Prof Dr LK Meher.pptxECG Basics with Prof Dr LK Meher.pptx
ECG Basics with Prof Dr LK Meher.pptxSubha Deep
 
ECG Basics with Dr LK Meher.pptx
ECG Basics with Dr LK Meher.pptxECG Basics with Dr LK Meher.pptx
ECG Basics with Dr LK Meher.pptxSubha Deep
 
Weaning from ventilaor.ppt
Weaning from ventilaor.pptWeaning from ventilaor.ppt
Weaning from ventilaor.pptSubha Deep
 
ALBUMIN-The Colloid Which Refuses to Go away .pptx
ALBUMIN-The Colloid Which Refuses to Go away .pptxALBUMIN-The Colloid Which Refuses to Go away .pptx
ALBUMIN-The Colloid Which Refuses to Go away .pptxSubha Deep
 
Orthopedic Splints and Casts- Subhadeep PGModules.pptx
Orthopedic Splints and Casts- Subhadeep PGModules.pptxOrthopedic Splints and Casts- Subhadeep PGModules.pptx
Orthopedic Splints and Casts- Subhadeep PGModules.pptxSubha Deep
 
Massive-Transfusion-in-Trauma-Guildelines.pdf
Massive-Transfusion-in-Trauma-Guildelines.pdfMassive-Transfusion-in-Trauma-Guildelines.pdf
Massive-Transfusion-in-Trauma-Guildelines.pdfSubha Deep
 
OP Poisoning Dr Subhadeep JR Emmed.pptx
OP Poisoning Dr Subhadeep JR Emmed.pptxOP Poisoning Dr Subhadeep JR Emmed.pptx
OP Poisoning Dr Subhadeep JR Emmed.pptxSubha Deep
 
Nutrition In COVID A Guideline Based Approach-DrSubhadeep
Nutrition In COVID A Guideline Based Approach-DrSubhadeepNutrition In COVID A Guideline Based Approach-DrSubhadeep
Nutrition In COVID A Guideline Based Approach-DrSubhadeepSubha Deep
 
Monkey pox.pdf
Monkey pox.pdfMonkey pox.pdf
Monkey pox.pdfSubha Deep
 
AEFI monitoring for COVID-19 vaccination
AEFI monitoring for COVID-19 vaccinationAEFI monitoring for COVID-19 vaccination
AEFI monitoring for COVID-19 vaccinationSubha Deep
 
WHO Vaccinator Module 2
WHO Vaccinator Module 2WHO Vaccinator Module 2
WHO Vaccinator Module 2Subha Deep
 
Nutrition in COVID-19 a Guideline and Practice Based Approach
Nutrition in COVID-19 a Guideline and Practice Based ApproachNutrition in COVID-19 a Guideline and Practice Based Approach
Nutrition in COVID-19 a Guideline and Practice Based ApproachSubha Deep
 
Oxygen Medical Use Guideline BTS
Oxygen Medical Use Guideline BTSOxygen Medical Use Guideline BTS
Oxygen Medical Use Guideline BTSSubha Deep
 
Algorithms AHA ACLS BLS Interim Guidelines for COVID
Algorithms AHA ACLS BLS Interim Guidelines for COVIDAlgorithms AHA ACLS BLS Interim Guidelines for COVID
Algorithms AHA ACLS BLS Interim Guidelines for COVIDSubha Deep
 
AHA ACLS BLS CPR Guideline 2020
AHA ACLS BLS CPR Guideline 2020AHA ACLS BLS CPR Guideline 2020
AHA ACLS BLS CPR Guideline 2020Subha Deep
 
Nutrition in icu closed system nutrition benefits
Nutrition in icu  closed system nutrition benefitsNutrition in icu  closed system nutrition benefits
Nutrition in icu closed system nutrition benefitsSubha Deep
 

Más de Subha Deep (16)

ECG Basics with Prof Dr LK Meher.pptx
ECG Basics with Prof Dr LK Meher.pptxECG Basics with Prof Dr LK Meher.pptx
ECG Basics with Prof Dr LK Meher.pptx
 
ECG Basics with Dr LK Meher.pptx
ECG Basics with Dr LK Meher.pptxECG Basics with Dr LK Meher.pptx
ECG Basics with Dr LK Meher.pptx
 
Weaning from ventilaor.ppt
Weaning from ventilaor.pptWeaning from ventilaor.ppt
Weaning from ventilaor.ppt
 
ALBUMIN-The Colloid Which Refuses to Go away .pptx
ALBUMIN-The Colloid Which Refuses to Go away .pptxALBUMIN-The Colloid Which Refuses to Go away .pptx
ALBUMIN-The Colloid Which Refuses to Go away .pptx
 
Orthopedic Splints and Casts- Subhadeep PGModules.pptx
Orthopedic Splints and Casts- Subhadeep PGModules.pptxOrthopedic Splints and Casts- Subhadeep PGModules.pptx
Orthopedic Splints and Casts- Subhadeep PGModules.pptx
 
Massive-Transfusion-in-Trauma-Guildelines.pdf
Massive-Transfusion-in-Trauma-Guildelines.pdfMassive-Transfusion-in-Trauma-Guildelines.pdf
Massive-Transfusion-in-Trauma-Guildelines.pdf
 
OP Poisoning Dr Subhadeep JR Emmed.pptx
OP Poisoning Dr Subhadeep JR Emmed.pptxOP Poisoning Dr Subhadeep JR Emmed.pptx
OP Poisoning Dr Subhadeep JR Emmed.pptx
 
Nutrition In COVID A Guideline Based Approach-DrSubhadeep
Nutrition In COVID A Guideline Based Approach-DrSubhadeepNutrition In COVID A Guideline Based Approach-DrSubhadeep
Nutrition In COVID A Guideline Based Approach-DrSubhadeep
 
Monkey pox.pdf
Monkey pox.pdfMonkey pox.pdf
Monkey pox.pdf
 
AEFI monitoring for COVID-19 vaccination
AEFI monitoring for COVID-19 vaccinationAEFI monitoring for COVID-19 vaccination
AEFI monitoring for COVID-19 vaccination
 
WHO Vaccinator Module 2
WHO Vaccinator Module 2WHO Vaccinator Module 2
WHO Vaccinator Module 2
 
Nutrition in COVID-19 a Guideline and Practice Based Approach
Nutrition in COVID-19 a Guideline and Practice Based ApproachNutrition in COVID-19 a Guideline and Practice Based Approach
Nutrition in COVID-19 a Guideline and Practice Based Approach
 
Oxygen Medical Use Guideline BTS
Oxygen Medical Use Guideline BTSOxygen Medical Use Guideline BTS
Oxygen Medical Use Guideline BTS
 
Algorithms AHA ACLS BLS Interim Guidelines for COVID
Algorithms AHA ACLS BLS Interim Guidelines for COVIDAlgorithms AHA ACLS BLS Interim Guidelines for COVID
Algorithms AHA ACLS BLS Interim Guidelines for COVID
 
AHA ACLS BLS CPR Guideline 2020
AHA ACLS BLS CPR Guideline 2020AHA ACLS BLS CPR Guideline 2020
AHA ACLS BLS CPR Guideline 2020
 
Nutrition in icu closed system nutrition benefits
Nutrition in icu  closed system nutrition benefitsNutrition in icu  closed system nutrition benefits
Nutrition in icu closed system nutrition benefits
 

Último

Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...christianmathematics
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfchloefrazer622
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
 
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...PsychoTech Services
 
social pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajansocial pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajanpragatimahajan3
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationnomboosow
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...Sapna Thakur
 
General AI for Medical Educators April 2024
General AI for Medical Educators April 2024General AI for Medical Educators April 2024
General AI for Medical Educators April 2024Janet Corral
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhikauryashika82
 

Último (20)

Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdf
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
 
social pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajansocial pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajan
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communication
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
 
General AI for Medical Educators April 2024
General AI for Medical Educators April 2024General AI for Medical Educators April 2024
General AI for Medical Educators April 2024
 
Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 

Figo staging systems

  • 1. REVISED FIGO STAGING SYSTEMS FOR GYNAECOLOGICAL CANCERS (2009) Glenn McCluggage, Belfast Trust
  • 2. BACKGROUND • Groups set up several years ago • March 2009-staging system for uterine sarcomas published (IJGO 2009;104;179)- PATHOLOGICAL INPUT • May 2009-staging systems for endometrial, cervical and vulval tumours published (IJGO 2009;105;103-104)- NO PATHOLOGICAL INPUT
  • 3. OTHER TUMOURS • groups set up to look at staging of ovarian, fallopian tube and trophoblastic neoplasms
  • 4. NEW FIGO STAGING FOR UTERINE SARCOMAS • never had staging system previously • carcinosarcomas staged as per uterine carcinomas • staging system for leiomyosarcomas • different system for ESS and adenosarcoma
  • 5. Leiomyosarcomas- FIGO 2009 Stage I Tumour limited to uterus IA <5 cm IB >5 cm Stage II Tumour extends to the pelvis IIA Adnexal involvement IIB Tumour extends to extrauterine pelvic tissue Stage III Tumour invades abdominal tissues (not just protruding into the abdomen) IIIA One site IIIB > one site IIIC Metastasis to pelvic and/or para-aortic lymph nodes Stage IV IVA Tumour invades bladder and/or rectum IVB Distant metastasis
  • 6. Endometrial stromal sarcomas (ESS) and adenosarcomas- FIGO 2009 Stage I Tumour limited to uterus IA Tumour limited to endometrium/endocervix with no myometrial invasion IB Less than or equal to half myometrial invasion IC More than half myometrial invasion Stage II Tumour extends to the pelvis IIA Adnexal involvement IIB Tumour extends to extrauterine pelvic tissue Stage III Tumour invades abdominal tissues (not just protruding into the abdomen) IIIA One site IIIB > one site IIIC Metastasis to pelvic and/or para-aortic lymph nodes Stage IV IVA Tumour invades bladder and/or rectum IVB Distant metastasis
  • 8. Carcinoma of the endometrium- FIGO 2009 Stage I Tumour confined to the corpus uteri IA No or less than half myometrial invasion IB Invasion equal to or more than half of the myometrium Stage II Tumour invades cervical stroma, but does not extend beyond the uterus Stage III Local and/or regional spread of the tumour IIIA Tumour invades the serosa of the corpus uteri and/or adnexae IIIB Vaginal and/or parametrial involvement IIIC Metastases to pelvic and/or para-aortic lymph nodes IIIC1 Positive pelvic nodes IIIC2 Positive para-aortic lymph nodes with or without positive pelvic lymph nodes Stage IV Tumour invades bladder and/or bowel mucosa, and/or distant metastases IVA Tumour invasion of bladder and/or bowel mucosa IVB Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes
  • 9. CHANGES TO STAGE I • old IA and IB is now IA (FIGO figures show no difference in outcome; pathological difficulties) • old IC is now IB • endocervical glandular involvement alone will still be stage I
  • 10. CHANGES TO STAGE II • single category of stage II (cervical stromal involvement)
  • 11. CHANGES TO STAGE III • IIIA- uterine serosal or adnexal involvement • IIIB- vaginal and/or parametrial involvement • IIIC- pelvic and/or para-aortic nodes (IIIC1-pelvic nodes; IIIC2- para-aortic nodes)
  • 12. CHANGES TO STAGE IV • none
  • 13. PERITONEAL WASHINGS • to be performed and reported separately ie not part of staging system • significance to be discussed at MDTM
  • 14.
  • 15. PATHOLOGY PROFORMAS • ? still include confined to endometrium or inner half of endometrium • ? still include cervical glandular involvement (? will be treated with radiotherapy)
  • 17. Carcinoma of the cervix uteri- FIGO 2009 Stage I The carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded) IA Invasive carcinoma which can be diagnosed only by microscopy, with deepest invasion <5 mm and the largest extension >7 mm IA1 Measured stromal invasion of <3.0 mm in depth and extension of <7.0 mm IA2 Measured stromal invasion of >3.0 mm and not >5.0 mm with an extension of not >7.0 mm IB Clinically visible lesions limited to the cervix uteri or pre-clinical cancers greater than stage IA IB1 Clinically visible lesion <4.0 cm in greatest dimension IB2 Clinically visible lesion >4.0 cm in greatest dimension Stage II Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or to the lower third of the vagina IIA Without parametrial invasion IIA1 Clinically visible lesion <4.0 cm in greatest dimension IIA2 Clinically visible lesion >4.0 cm in greatest dimension IIB With obvious parametrial invasion
  • 18. Stage III The tumour extends to the pelvic wall and/or involves lower third of the vagina and/or causes hydronephrosis or non-functioning kidney IIIA Tumour involves lower third of the vagina, with no extension to the pelvic wall IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney Stage IV The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous oedema, as such, does not permit a case to be allotted to Stage IV IVA Spread of the growth to adjacent organs IVB Spread to distant organs
  • 20. CHANGES TO STAGE I • none
  • 21. CHANGES TO STAGE II • IIA- without parametrial invasion ie vaginal involvement (IIA1- < 4cm; IIA2- >4cm)
  • 22. CHANGES TO STAGE III • none
  • 23. CHANGES TO STAGE IV • none
  • 24. VULVAL CARCINOMA • MUCH MORE COMPLICATED • significant changes
  • 25. Carcinoma of the vulva- FIGO 2009 Stage I Tumour confined to the vulva IA Lesions <2 cm in size, confined to the vulva or perineum and with stromal invasions <1.0 mm*, no nodal metastasis IB Lesions >2 cm in size or with stromal invasion >1.0 mm* confined to the vulva or perineum, with negative nodes Stage II Tumour of any size with extension to adjacent perineal structures (1/3 lower urethra, 1/3 lower vagina, anus) with negative nodes Stage III Tumour of any size with or without extension to adjacent perineal structures (1/3 lower urethra, 1/3 lower vagina, anus) with positive inguino-femoral lymph nodes. IIIA (i) With 1 lymph node metastasis (>5 mm), or (ii) 1-2 lymph node metastasis(es) (<5 mm) IIIB (i) With 2 or more lymph node metastases (>5 mm), or (ii) 3 or more lymph node metastases (<5 mm) IIIC With positive nodes with extracapsular spread Stage IV Tumour invades other regional (2/3 upper urethra, 2/3 upper vagina), or distant structures. IVA Tumour invades any of the following: (i) upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, or fixed to pelvic bone, or (ii) fixed or ulcerated inguino-femoral lymph nodes IVB Any distant metastasis including pelvic lymph nodes * The depth of invasion is defined as the measurement of the tumour from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion.
  • 26. CHANGES TO STAGE I • IA- < 2cm, stromal invasion <1mm, confined to vulval or perineum, no nodal metastasis • IB- previous IB and II combined- >2cm size or with stromal invasion >1mm, confined to vulval or perineum, no nodal metastasis
  • 27. CHANGES TO STAGE II • any size with extension to lower third of urethra, lower third of vagina or anus and negative nodes
  • 28. CHANGES TO STAGE III • any size, with or without extension to lower third of urethra, lower third of vagina or anus and positive inguino-femoral nodes • IIIA- 1 nodal metastasis > 5mm or up to 2 nodes <5mm • IIIB- 2 or more nodes >5mm or 3 or more nodes <5mm • IIIC- extracapsular spread
  • 29. CHANGES TO STAGE IV • upper two thirds of urethra or vagina or distant structures • various substages • bilateral nodal involvement now not taken into account
  • 30. IMPLICATIONS/DIFFICULTIES • dissemination of information to surgical oncologists, gynaecologists, non-surgical oncologists, pathologists, radiologists • ? set start date • endocervical glandular involvement in endometrial cancer (marked interobserver variation) • pathologists difficulty in distinguishing cervical glandular from stromal involvement • TNM will differ for a while- will be updated in 7th TNM edition (? drop TNM from pathology proformas)
  • 31. WIDER QUESTIONS • rest of UK (role of British Gynaecological Cancer Society, British Association of Gynaecological Pathologists) • if piecemeal introduction, will create difficulties